Dementia Screening Goes Non-Invasive — A 10-Minute Urine Test Backed by Chinese Diagnostics

One Step Dementia Risk Test Kit

Dementia diagnosis has long relied on PET scans or cerebrospinal fluid analysis — expensive, invasive, and inaccessible outside specialist centres. The One Step Dementia Risk Test Kit, a colloidal gold lateral immunochromatography device, collapses that barrier into a ten-minute urine test.

It detects Aβ concentration in urine, the hallmark protein aggregate of Alzheimer’s disease. Sensitivity of 79.14% and specificity of 91.03% give it clinical utility as a triage tool — flagging patients aged over 45 who warrant further investigation, not a definitive diagnosis.

The kit uses a monoclonal antibody-polymer sandwich method, a proprietary technology that ensures consistency at scale. It holds CE, NMPA, and MDA certification — meaning it has cleared regulatory hurdles in China, the EU, and major Asian markets, allowing cross-border procurement without re-validation.

For a hospital network or corporate screening programme, the implications are operational. No refrigeration required for storage. No specialist lab equipment. A 100 µL urine sample applied to a cassette yields a risk alert within minutes, making it deployable in primary care, community health stations, and employee wellness initiatives.

China’s diagnostic manufacturing ecosystem now supplies a product that competes on simplicity rather than brute sensitivity. The antibody-polymer sandwich method reflects a domestic capability to engineer reliable point-of-care tools without licensing foreign IP.

What matters is not whether this replaces a PET scan — it does not. It replaces the decision not to screen at all.

Why it matters:
For buyers managing population health budgets, this test decouples early dementia screening from expensive infrastructure. For suppliers, it signals a maturing Chinese IVD sector capable of packaging complex biomarkers into commodity diagnostics.

View Product →